Idisan

Icatibant, the active ingredient in Idisan, is a bradykinin B2 receptor antagonist presented as a subcutaneous solution for subcutaneous use. It is indicated for the treatment of hereditary angioedema attacks in patients with a confirmed diagnosis.

GNH USA supplies Idisan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution. Clients benefit from reliable logistics and comprehensive documentation.

Idisan is used to manage acute episodes within the hereditary angioedema (HAE) disease pathway.

- Hereditary angioedema (HAE) attacks: rapid reduction of swelling and improvement of airway patency. - Hereditary angioedema type I: alleviates edema during acute crises. - Hereditary angioedema type II: controls sudden swelling episodes.

Common and serious adverse reactions have been reported with subcutaneous icatibant administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling at injection site: localized erythema. - Nausea: occasional feeling of queasiness. - Headache: transient head discomfort. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or anaphylaxis. - Severe hypotension: marked drop in blood pressure. - Angioedema paradoxically: swelling of face, lips, or airway. - Thrombocytopenia: low platelet count. - Acute myocardial infarction: rare cardiac event.

Before prescribing Idisan, clinicians should consider several precautionary measures.

- Confirm diagnosis of hereditary angioedema: ensure appropriate indication. - Assess for known hypersensitivity to icatibant or excipients: avoid use if present. - Monitor cardiovascular status: use cautiously in patients with unstable heart disease. - Evaluate pregnancy and lactation status: risk unknown, weigh benefits and risks. - Review concomitant ACE inhibitor therapy: consider alternative due to increased bradykinin risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medicines that affect the bradykinin pathway or cardiovascular system.

Major Interactions (Avoid): - ACE inhibitors: increased risk of angioedema. - Angiotensin receptor blockers (ARBs): potential additive bradykinin effects. - Other bradykinin B2 receptor antagonists: may reduce efficacy.

Moderate Interactions (Monitor Closely): - Estrogen‑containing oral contraceptives: may exacerbate HAE symptoms. - Hormone replacement therapy: monitor for swelling episodes. - Diuretics: watch for changes in blood pressure.